PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS
申请人:Genentech, Inc.
公开号:US20140080829A1
公开(公告)日:2014-03-20
The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof.
Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
申请人:Bencsik Josef
公开号:US08618097B2
公开(公告)日:2013-12-31
The present invention provides compounds of Formula (I), including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
QUINAZOLINE COMPOUNDS AS SERINE/THREONINE KINASE INHIBITORS
申请人:Blake James F.
公开号:US20150087664A1
公开(公告)日:2015-03-26
Compounds having the formula (I) wherein R
1
, R
2
, R
3
and Ar as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.